Skip to Content
Merck
All Photos(1)

Key Documents

Y0001294

Iodixanol

European Pharmacopoeia (EP) Reference Standard

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C35H44I6N6O15
CAS Number:
Molecular Weight:
1550.18
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

iodixanol

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

InChI

1S/C35H44I6N6O15/c1-13(52)46(30-26(38)20(32(59)42-3-15(54)9-48)24(36)21(27(30)39)33(60)43-4-16(55)10-49)7-19(58)8-47(14(2)53)31-28(40)22(34(61)44-5-17(56)11-50)25(37)23(29(31)41)35(62)45-6-18(57)12-51/h15-19,48-51,54-58H,3-12H2,1-2H3,(H,42,59)(H,43,60)(H,44,61)(H,45,62)

InChI key

NBQNWMBBSKPBAY-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Iodixanol EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Storage Class Code

11 - Combustible Solids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Kartik Jhaveri et al.
AJR. American journal of roentgenology, 201(2), W292-W296 (2013-07-26)
The purpose of this study is to evaluate the interval growth, tumor recurrence, and metastatic disease occurrence of cystic renal cell carcinoma (RCC). Pre-and posttreatment imaging of 47 histologically proven cystic RCCs, with at least 6 months of pretreatment imaging
Sonja M Kandel et al.
Radiology, 270(1), 125-130 (2013-09-14)
To analyze the effect of the duration of contrast material bolus injection on perfusion values in a swine model by using the maximum slope method. This study was approved by the institutional animal care committee. Twenty pigs (weight range, 63-77
Hyun-Jung Jang et al.
AJR. American journal of roentgenology, 201(2), 314-321 (2013-07-26)
The purpose of this study was to identify the essential number of phases from multiphasic CT for 1- to 2-cm hepatocellular carcinoma (HCC) on surveillance ultrasound and to compare the results with the American Association for the Study of Liver
Erica M Weekman et al.
Journal of neuroinflammation, 11, 127-127 (2014-07-27)
The polarization to different neuroinflammatory phenotypes has been described in early Alzheimer's disease, yet the impact of these phenotypes on amyloid-beta (Aβ) pathology remains unknown. Short-term studies show that induction of an M1 neuroinflammatory phenotype reduces Aβ, but long-term studies
Jill Rachel Mains et al.
Investigative radiology, 49(9), 601-607 (2014-04-03)
The aim of this study was to explore the impact of dynamic contrast-enhanced (DCE) computer tomography (CT) as a biomarker in metastatic renal cell carcinoma (mRCC). Twelve patients with favorable or intermediate Memorial Sloan Kettering Cancer Center risk group and

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service